Multiple sclerosis: TOWER confirms the efficacy of oral teriflunomide in MS
- PMID: 24638132
- DOI: 10.1038/nrneurol.2014.42
Multiple sclerosis: TOWER confirms the efficacy of oral teriflunomide in MS
Comment on
-
Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Neurol. 2014 Mar;13(3):247-56. doi: 10.1016/S1474-4422(13)70308-9. Epub 2014 Jan 23. Lancet Neurol. 2014. PMID: 24461574 Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
